 BIM deletion polymorphism might be associated with a poor clinical response to EGFR-TKIs in patients who had NSCLC with EGFR mutations. In the study, the investigators want to use EGFR-TKI withwithout chemotherapy as first line treatment in stage IIIBIV NSCLC patients with both EGFR mutation and BIM deletion polymorphism. 